Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (vol 29, pg 351, 2011)

Isakoff Steven J.; Baselga Jose

首页> 外文期刊>Journal of Clinical Oncology >Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (vol 29, pg 351, 2011)

【24h】

Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (vol 29, pg 351, 2011)

机译：Trastuzumab-DM1：在治疗人体表皮生长因子受体2阳性乳腺癌（Vol 29，PG 351,2011）中建立一种无疗效的道路

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Journal of Clinical Oncology》 |2019年第4期|共1页
作者
Isakoff Steven J.; Baselga Jose;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (vol 29, pg 351, 2011) [J] . Isakoff Steven J., Baselga Jose Journal of Clinical Oncology . 2019,第4期

机译：Trastuzumab-DM1：在治疗人体表皮生长因子受体2阳性乳腺癌（Vol 29，PG 351,2011）中建立一种无疗效的道路
2. Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (vol 33, pg 1712, 2015) [J] . Baselga J., Clark E., Kiermaier A., Journal of Clinical Oncology . 2019,第4期

机译：Trastuzumab-DM1：在治疗人体表皮生长因子受体2阳性乳腺癌（第33 Vol 33，PG 1712,2015）中，建立一种无化疗的道路
3. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. [J] . Isakoff SJ, Baselga J Journal of Clinical Oncology . 2011,第4期

机译：曲妥珠单抗-DM1：在人类表皮生长因子受体2阳性乳腺癌的治疗中建立无化学疗法之路。
4. Identification of Human Epidermal Growth Factor Receptor 2 Antagonist In Silico for Breast Cancer Therapy, Derived from Indonesian Phytochemicals [C] . Tuti Ratnasari, Dono indarto, Raden Ajeng Sri Wulandari, International Conference on Biomedical Engineering . 2018

机译：人类表皮生长因子受体2拮抗剂在二氧化硅中用于印尼治疗的印尼植物化学成分的鉴定。
5. Indirect Costs Associated with Human Epidermal Growth Factor Receptor Positive (HER2+) Metastatic Breast Cancer [D] . Wright, Phoebe. 2020

机译：与人表皮生长因子受体阳性（HER2 +）转移性乳腺癌相关的间接成本
6. Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review [O] . Xiao Zhang, Xin-Ji Zhang, Tian-Yi Zhang, 2014

机译：与单药治疗相比双重抗人表皮生长因子受体2疗法对人表皮生长因子受体2阳性乳腺癌的疗效和安全性：系统评价
7. Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review [O] . Xiao Zhang, Xin-Ji Zhang, Tian-Yi Zhang, 2014

机译：与单药治疗相比，双重抗人表皮生长因子受体2疗法对人表皮生长因子受体2阳性乳腺癌的疗效和安全性：系统评价

Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (vol 29, pg 351, 2011)

著录项

引文网络

相似文献

相关主题

期刊订阅